FDA Committee Recommends COVID-19 Vaccines Should Be Monovalent, Contain the XBB Strain
The FDA committee, known as VRBPAC, in charge of evaluating vaccines and related biological products recently voted unanimously that the upcoming 2023-2024 COVID-19 vaccines should be updated with a monovalent XBB strain.